The case for & against
Bull & Bear analysis
Bullish
Cybin Inc. (NASDAQ: HELP), operating as Helus Pharma, is an emerging player in the pharmaceutical sector, specifically focused on developing psychedelic-based treatments for mental health disorders. The company primarily targets major depressive disorder (MDD) and generalized anxiety disorder (GAD). Positioned at the forefront of the burgeoning mental health treatment landscape, Helus Pharma seeks to leverage the therapeutic potential of psychedelics to transform patient outcomes in this space, which is rapidly gaining recognition amid increasing research and acceptance.
Bull says
- ↑Phase 3 APPROACH trial for HLP003 in MDD completed enrollment; topline readout due Q4 2026
- ↑Consensus Buy rating with $45.25 target implies ~295% upside
- ↑Analysts foresee rising earnings revisions ahead of Phase 2 HLP004 GAD data
- ↑Dividend yield 1.32% offers income support during development phase
- ↑Cash balance $166.4 M funds R&D and buffers short-term burn
- ↑Institutional interest and positive momentum improve liquidity and trading trends
Bear says
- ↓Q1 FY27 net loss $47.8 M underscores persistent cash burn
- ↓Negative profitability and earnings yield signal weak operational efficiency
- ↓High leverage raises refinancing risk amid potential rate hikes
- ↓Weak growth outlook may delay path to positive EBITDA
- ↓Elevated short interest reflects growing investor skepticism
- ↓Trial setbacks or regulatory shifts could trigger stock volatility